Could one year of immunotherapy be enough for advanced melanoma?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with malignant melanoma (with confirmed histopathological diagnosis) stages III and IV not amenable to locoregional treatment or curative treatment * Measurable disease by RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2 * Up to 1 (one) line of prior treatment with palliative chemotherapy (monotherapy), with documented progression and no residual toxicities greater than grade 1 according to CTCAE * Estimated life expectancy greater than 12 weeks * Adequate renal function, defined as creatinine clearance estimated by the Cockcroft-Gault equation equal to or greater than 30 mL/min; * Adequate liver function, defined as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels equal to or less than 2.0 times the upper limit of normal and total bilirubin less than 2 times the upper limit of normal; * Hemoglobin greater than or equal to 8 g/dL; neutrophil count equal to or greater than 1,000/mm3; platelet count equal to or greater than 100,000/mm3; * Ability to understand and adhere to study procedures; * Age over 18 years; * Absence of active treatment for the underlying disease, with the exception of the use of bisphosphonates; Exclusion Criteria: * Uncontrolled Central Nervous System (CNS) metastases: active symptomatic disease in the central nervous system, requiring doses of corticosteroids greater than the equivalent of 10 mg/day of prednisone. Patients previously submitted to local treatment, such as radiotherapy, will be eligible if they have demonstrated clinical stability in the 2 weeks prior to the start of treatment; * Diagnosis of uveal or mucosal melanoma; * Diagnosis of acral melanoma; * Leptomeningeal disease * Pregnancy; effective contraceptive methods should be recommended to women of childbearing age; * Uncontrolled associated disease; * Known active hepatitis B and C; * HIV with detectable viral load or CD4\<350; * Active autoimmune disease with use of immunosuppressive therapy or history of autoimmune disease whose risk of recurrence is considered high by the investigator; * More than one line of prior systemic therapy in the context of metastatic or advanced disease or prior use of polychemotherapy; * Prior use of anti-PD-1 in the (neo)adjuvant setting; * Concomitant active malignant neoplasia; * History of malignant neoplasia in the last 5 years, with the exception of squamous cell carcinoma, basal cell carcinoma of the skin, in situ tumors, prostate adenocarcinoma gleason \<=6; * Infection with systemic involvement in the last 2 weeks; * Use of corticosteroids in a dose equivalent to greater than 10 mg/d of prednisone on a continuous basis. * History of solid organ transplantation under immunosuppression.